respectively. Each of the three factors and the BG item discriminated between those patients who preferred inhaled insulin and those who preferred injectable insulin (all p < 0.001). Factors one and three and the BG item demonstrated the ability to detect change from baseline (injectable treatment) to following treatment with inhaled insulin (all p < 0.001). Factor analysis and interscale correlations indicated that the 16 items could be summed to a total IDSQ score. Cronbach's alpha for the total score was 0.93. CONCLUSION: The IDSQ is a reliable and valid instrument to assess insulin delivery system satisfaction in patients with type-1 diabetes. OBJECTIVES: Public health education is a cornerstone in primary prevention of diabetes mellitus (DM). However, valid and reliable tools to evaluate outcomes of DM education among the general public are lacking. We aim to evaluate the reliability and validity of the General Diabetes Knowledge Test (GDKT) for use among subjects with and without DM. METHODS: The GDKT is a 36-item questionnaire (range 0-100) constructed based on existing public DM education materials and covers six content areas: overview, risk factors, symptoms, complications, management and monitoring (for both Type-1 and 2 DM). To achieve wide representation, English-speaking subjects (aged > 21) were recruited by convenience sampling at a public health promotion event. The GDKT was first administered to 54 DM and 42 non-DM subjects. Eighteen subjects voluntarily participated in retest (all were DM). Internal consistency of GDKT was assessed using Kuder-Richardson Formula 20 (KRF20). Item difficulty was assessed by calculating the ratio of number of correct answers to number of respondents, range 0.00 (most difficult) to 1.00 (least difficult) and compared between DM and non-DM subjects using Students' t-test. Test-retest reliability was assessed using intraclass correlation coefficient (ICC). Construct validity was assessed using a known-group approach where DM subjects were expected to have higher GDKT scores than non-DM subjects. RESULTS: Internal consistency of GDKT was high (KRF20 = 0.9289). Item difficulty ranged from 0.59-0.97 and was significantly different (p < 0.05) between subjects with and without DM for 8 items. Test-retest reliability was moderate (ICC = 0.54, median = 94.4, range = 72.2-100.0, 95% CI: 0.77). Mean scores at first (91.8 ± 9.83) and second (93.3 ± 1.24) administrations were not significantly different (p = 0.38). As expected, DM subjects reported better mean (±SD) GDKT scores (90.8 ± 11.35) compared to non-DM subjects (85.7 ± 20.80) although the difference was not statistically significant (p = 0.13). CONCLU-SION: The internal consistency and construct validity of the GDKT was demonstrated in this study.
Palmer AJ 1 , Lammert M 2 , Minshall M 3 , Roze S 1 , Nicklasson L 4 , Valentine WJ 1 1 CORE-Center for Outcomes Research, Binningen, Basel, Switzerland; 2 Novo Nordisk A/S, Bagsvaerd, Denmark; 3 CORE-Centre for Outcomes Research, Fishers, IN, USA; 4 Novo Nordisk Inc, Princeton, NJ, USA OBJECTIVES: The aim of this study was evaluate the long-term costs and clinical outcomes of using either insulin aspart or human insulin (HI) at mealtimes in patients with type-1 diabetes, based on the clinical findings of a multicentre, randomized, openlabel comparative trial in 882 patients, which showed that mean (±SEM) HbA1c was lower after 12 months with insulin aspart than with HI (7.78 ± 0.03 versus 7.93 ± 0.05, P = 0.005). METHODS: Long-term clinical and cost outcomes were estimated using the CORE Diabetes Model, a peer-reviewed, validated model that employs standard Markov/Monte Carlo simulation techniques to describe the incidence and progression of diabetes-related complications. Transition probabilities were derived from major clinical studies. Published country-specific costs, health care resource utilization, clinical data and recommended discount rates were used. A lifetime horizon and third party payer perspective was taken (direct costs only). Extensive sensitivity analyses were performed. RESULTS: Discounted quality-adjusted life expectancy (QALE) was improved by 0.08 to 0.22 years with insulin aspart versus HI in the nine countries investigated. Lifetime cost savings were observed with insulin aspart in the Austrian, Dutch, French, and Norwegian settings. Overall costs were increased with insulin aspart versus HI in Denmark, Finland, Germany, Spain and Sweden, with incremental cost-effectiveness ratios of DKK20,814, €4434, €9553, €20,916 and SEK32,541 per QALY gained respectively. CON-CLUSIONS: Improvements in glycemic control associated with insulin aspart led to improved QALE due to reduced incidence of complications versus HI. Insulin aspart was projected to be either cost-saving or cost-effective compared to HI over patient lifetimes according to accepted international thresholds.
PDB38 MEASURING THE EFFECT OF THE VARIABILITY OF INSULIN USE ON HEALTH CARE COSTS IN DIABETES
Curkendall S 1 , Sarocco P 2 , Goldberg GA 3 , Patton MP 3 1 Healthcare Data Analysis, Vienna, VA, USA; 2 Sanofi-Aventis US Pharma, Bridgewater, NJ, USA; 3 i3 Magnifi, Reston, VA, USA OBJECTIVES: Using claims data, develop a measure of variability in insulin use that could be used as a proxy measure of non-adherence to insulin. Measure the effect of variability of insulin use on total and diabetes-attributable health care costs in a managed care population. METHODS: Using a large managed care administrative claims database, all patients with a prescription for long-or intermediate-acting insulin from January, 2000 through June, 2001 were selected (n = 12,336) from among continuously eligible patients age 18 years and older. Total insulin units dispensed with each prescription were computed by multiplying quantity (ml) from the claims data and strength (units/ml) from NDC reference data. Units-per-day were computed for each prescription pair by dividing units dispensed by the number of days until the next prescription. A time series of units-per-day was created for each patient during a one year follow-up period.
